Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
498
Employees498
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
498
Employees498

CYTK Key Statistics

Market cap
7.84B
Market cap7.84B
Price-Earnings ratio
-10.16
Price-Earnings ratio-10.16
Dividend yield
Dividend yield
Average volume
1.66M
Average volume1.66M
High today
$66.37
High today$66.37
Low today
$63.52
Low today$63.52
Open price
$65.85
Open price$65.85
Volume
1.50M
Volume1.50M
52 Week high
$69.33
52 Week high$69.33
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

With a market cap of 7.84B, Cytokinetics(CYTK) trades at $64.12. The stock has a price-to-earnings ratio of -10.16.

On 2025-12-09, Cytokinetics(CYTK) stock moved within a range of $63.52 to $66.37. With shares now at $64.12, the stock is trading +0.9% above its intraday low and -3.4% below the session's peak.

Trading volume for Cytokinetics(CYTK) stock has reached 1.5M, versus its average volume of 1.66M.

The stock's 52-week range extends from a low of $29.31 to a high of $69.33.

The stock's 52-week range extends from a low of $29.31 to a high of $69.33.

CYTK News

Simply Wall St 2d
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story?

In recent days, Grabar Law Office began investigating Cytokinetics, Inc. for potential breaches of fiduciary duty related to allegedly misleading disclosures ab...

Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story?
TipRanks 3d
Top Executive Sells Massive Stake in Cytokinetics!

New insider activity at Cytokinetics ( (CYTK) ) has taken place on December 5, 2025. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed i...

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
23.8%
Sell
0%

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.